{"title":"Pharmacogenomics as a Design Input in Early-Phase Drug Development","authors":"Amalia M. Issa PhD, MPH, FCP","doi":"10.1002/cpdd.70125","DOIUrl":"10.1002/cpdd.70125","url":null,"abstract":"<p>For much of my career in pharmacogenomics and precision medicine, it has been the field that was always about to arrive.<span><sup>1</sup></span> Every few years a new guideline, a new genotyping platform, or a new drug label change made it feel imminent. Meanwhile, patients still start drugs without systematic consideration of the genetic determinants of clearance, activation, or disposition.</p><p>Every investigational drug is, in a meaningful sense, studied in a genetically heterogeneous population. The first participants exposed to a new molecule carry distinct complements of drug-metabolizing enzymes, transporters, and receptors, and variation in these proteins can influence absorption, clearance, exposure, and response. This is not a new observation. The unresolved question is why pharmacogenomic information is still so often generated after the decisions it could most usefully inform have already been made.</p><p>In this editorial, I argue that pharmacogenomics should function as a prospective design input in Phase 1 and Phase 2 development, the period in which pharmacokinetic/pharmacodynamic (PK/PD) relationships are first characterized, dose-ranging decisions are made, and the architecture of the later program is established. In practice, genotype data remain too frequently collected late, analyzed post hoc, or invoked to explain an unanticipated Phase 2 finding rather than to shape the study that produced it.</p><p>The rationale for earlier integration is that the tools, modeling methods, and regulatory expectations have matured to the point where deferring these questions is increasingly difficult to justify.</p><p>The FDA guidance on clinical pharmacogenomics in early-phase studies articulates the underlying logic. Phase 1 and 2 studies are exploratory and may be underpowered to detect modest genotype effects, but they can identify large effects and are well positioned to characterize sources of variability before a larger development program is designed around incomplete assumptions. Where evidence supports it, the guidance encourages genotype-stratified dosing or genotype-guided exposure–response evaluation and emphasizes that such questions are best addressed early in discovery and development.<span><sup>2</sup></span></p><p>The FDA's Table of Pharmacogenomic Biomarkers in Drug Labeling illustrates the practical consequences of this timing. It catalogs biomarkers that regulators have highlighted in labeling across therapeutic areas, including biomarkers associated with drug exposure, clinical response, and risk of adverse effects.<span><sup>3</sup></span> The relevant question for drug developers is therefore not whether such associations exist, but how many could have been anticipated during early-phase development, and what study design would have been required to detect them.</p><p>The mechanistic implications are straightforward. When a candidate is cleared predominantly by a polymorphic enzyme, an early-phase study that doe","PeriodicalId":10495,"journal":{"name":"Clinical Pharmacology in Drug Development","volume":"15 11","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cpdd.70125","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149341150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abhijit Chakraborty, Anshu Marathe, Jong Bong Lee, Kari Wiedinger, Britta Zehnpfennig, Carole Schuhler, Simantini Eddy, Michelle Quinlan
{"title":"Comparability of Pharmacokinetics, Safety, and Tolerability of Canakinumab Administration With One Injection (200 mg) of Pre-Filled Syringe or Auto-Injector Versus Two Injections (150 and 50 mg) of Pre-Filled Syringe in Healthy Subjects","authors":"Abhijit Chakraborty, Anshu Marathe, Jong Bong Lee, Kari Wiedinger, Britta Zehnpfennig, Carole Schuhler, Simantini Eddy, Michelle Quinlan","doi":"10.1002/cpdd.70109","DOIUrl":"10.1002/cpdd.70109","url":null,"abstract":"<p>This phase 1, randomized, open-label, single-dose, parallel-group study aimed to describe the pharmacokinetic (PK) comparability and safety of canakinumab administered as a single 200 mg subcutaneous injection via pre-filled syringes assembled within a needle safety device (PFS-NSD) by HCP and auto-injector (AI) by subject self-administration versus two injections of 150 + 50 mg via PFS-NSD by HCP. Healthy adults (18–55 years) were allocated to three arms: canakinumab 150 + 50 mg (PFS-NSD; n = 78), canakinumab 200 mg (AI; n = 76), and canakinumab 200 mg (PFS-NSD; n = 76). Multiplicity was addressed as two tests were compared with the same reference. Primary PK parameters were comparable across arms. The geometric mean ratios and 95% CI values of AUC<sub>inf</sub>, AUC<sub>last</sub>, and C<sub>max</sub> were within bioequivalence limits of 0.80-1.25 for both comparisons: (a) canakinumab 200 mg AI versus canakinumab 150 + 50 mg PFS-NSD and (b) canakinumab 200 mg PFS-NSD versus canakinumab 150 + 50 mg PFS-NSD. Median T<sub>max</sub> was comparable: 7, 9, and 7 days for canakinumab 150 + 50 mg PFS-NSD, 200 mg AI, and 200 mg PFS-NSD, respectively. Exploratory post-hoc analyses, assessing the impact of pause during the pandemic (N = 131 subjects recruited pre-pandemic) and evaluating partial AUC<sub>4weeks</sub>, suggested similar results. Canakinumab was well-tolerated, and no treatment-induced immunogenicity was observed.</p>","PeriodicalId":10495,"journal":{"name":"Clinical Pharmacology in Drug Development","volume":"15 11","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Drug-Drug Interaction Assessment of WXFL10203614 With Rifampicin, Itraconazole and Metformin: A Three-Cohort Phase I Study.","authors":"Jinmei Zhou, Mengshuang Gao, Daolei Zhou, Zhiwei Zhang, Huan Zhang, Yu Sun, Huan Zhou","doi":"10.1002/cpdd.70119","DOIUrl":"10.1002/cpdd.70119","url":null,"abstract":"<p><p>To evaluate the effects of rifampicin and itraconazole on the pharmacokinetics (PK) of the Janus kinase 1 (JAK1) inhibitor WXFL10203614 and the effects of steady-state WXFL10203614 on metformin PK and safety. In this single-center, open-label, fixed-sequence, self-controlled Phase I study, 54 healthy participants were enrolled into three cohorts. Plasma and urine drug concentrations were measured using validated liquid chromatography-tandem mass spectrometry. Drug-drug interactions were assessed using geometric mean ratios and 90% confidence intervals for prespecified PK parameters. Rifampicin reduced WXFL10203614 systemic exposure by approximately 40% and shortened its elimination half-life by 39%, whereas itraconazole increased exposure by approximately 26%. Changes in C<sub>max</sub> were less pronounced, suggesting that altered systemic clearance contributed substantially to these interactions. Steady-state WXFL10203614 did not meaningfully alter metformin plasma exposure but reduced metformin renal clearance and cumulative urinary excretion by approximately 36% and 30%, respectively, consistent with an effect on renal tubular secretion involving MATE1/MATE2-K. No serious adverse events occurred, and most treatment-emergent adverse events were Grade 1. WXFL10203614 was sensitive to CYP3A induction, whereas the effect of CYP3A inhibition was modest. Concomitant use with strong CYP3A inducers should be avoided where possible. The reduced renal clearance and urinary excretion of metformin support consideration of MATE-mediated interactions when WXFL10203614 is co-administered with metformin or other relevant transporter substrates.</p>","PeriodicalId":10495,"journal":{"name":"Clinical Pharmacology in Drug Development","volume":"15 11","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joseph F. Grippo, Anja Pfaff, Zhongli Xu, Isabell Otto, Claus Thielert, Mihaly Imre, Rui Liu, Wantanee Phuapradit, Yazhong Pei, Cuie Chen, Maria Habel, Renfeng Guo, Camilla Chong
{"title":"A First-In-Human, Randomized, Placebo-Controlled Single and Multiple Ascending Dose Study of Izicopan (INF904), A Second-Generation Oral Small Molecule C5a Receptor Inhibitor, in Healthy Participants","authors":"Joseph F. Grippo, Anja Pfaff, Zhongli Xu, Isabell Otto, Claus Thielert, Mihaly Imre, Rui Liu, Wantanee Phuapradit, Yazhong Pei, Cuie Chen, Maria Habel, Renfeng Guo, Camilla Chong","doi":"10.1002/cpdd.70123","DOIUrl":"https://doi.org/10.1002/cpdd.70123","url":null,"abstract":"<p>This was a first-in-human, single-center, Phase 1 study of izicopan (formerly INF904), a potent oral, second-generation small molecule antagonist of C5aR1, in healthy adults. Participants were randomized to a single oral dose of izicopan 3–240 mg or matched placebo (single ascending dose [SAD]), or multiple doses of izicopan 30 mg once daily (QD), 30 or 90 mg twice daily (BID), or matched placebo, for 14 days (multiple ascending dose [MAD]). In the SAD study, izicopan plasma concentration increased with dose from 3 to 240 mg; the mean maximum plasma concentration (C<sub>max</sub>) was 21.5–1216.0 ng/mL, reached at a median time (t<sub>max</sub>) of 3.5–6.0 h, followed by a biphasic decline. In the MAD study, a steady state appeared to have been reached within 14 days, and AUC<sub>0-tau</sub> exhibited an accumulation ratio of ∼2-fold following BID dosing, suggesting an effective half-life of ∼12 h. In an ex vivo whole blood PD assay, izicopan resulted in >90% blockade of CD11b upregulation by recombinant human C5a across almost all dose cohorts from Days 2–15. Adverse events were mild or moderate in severity. In conclusion, izicopan was safe across all single and multiple doses evaluated. Sufficient izicopan exposure was achieved rapidly to exert >90% blockade of C5a-C5aR1 signaling.</p>","PeriodicalId":10495,"journal":{"name":"Clinical Pharmacology in Drug Development","volume":"15 11","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149310823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jart A. F. Oosterhaven, Jonathan Trolander, Lidiya Bebrevska, Hilmar Schiller, Begum Alaybeyoglu, Suzanne Gaudet, Allison Claas, Kamal Kumar Balavenkatraman, Renee Bergeron, Fernanda V. Duraes, Frederique Chaperon, Swati Ghanshani, Elisabete Goncalves, Steven J. Kovacs
{"title":"Safety, Tolerability, and Pharmacokinetics of EGT710, a Novel Coronavirus Mpro Inhibitor, in Healthy Adults: A Randomized, Single- and Multiple-Dose Study","authors":"Jart A. F. Oosterhaven, Jonathan Trolander, Lidiya Bebrevska, Hilmar Schiller, Begum Alaybeyoglu, Suzanne Gaudet, Allison Claas, Kamal Kumar Balavenkatraman, Renee Bergeron, Fernanda V. Duraes, Frederique Chaperon, Swati Ghanshani, Elisabete Goncalves, Steven J. Kovacs","doi":"10.1002/cpdd.70115","DOIUrl":"https://doi.org/10.1002/cpdd.70115","url":null,"abstract":"<p>Antiviral therapy is needed to address acute coronavirus disease. EGT710 is a novel low-molecular-weight inhibitor of the coronavirus main protease (M<sup>pro</sup>). This first-in-human study evaluated the safety, tolerability, and pharmacokinetics of EGT710 in healthy adults. The study conducted in the Netherlands involved three parts: a blinded, placebo-controlled, 3:1 randomized, single ascending dose Part A (n = 39); a multiple ascending dose Part B (n = 31); and an open-label, three-period, six sequence, randomized, cross-over Part C (n = 18) to evaluate food and formulation effects on EGT710 bioavailability. EGT710 was well tolerated. All adverse events (AEs) were mild (Grade 1), with no serious AEs or discontinuations. Aside from mild gastrointestinal AEs associated with EGT710, AE frequency was similar between groups with no dose-dependent or dose-limiting adverse effects. EGT710 was rapidly absorbed (median T<sub>max</sub> 2.0 h), showed sub-proportional AUC and C<sub>max</sub> increases and no significant accumulation with daily dosing. Bioavailability was comparable between suspension and capsule formulations. Food increased C<sub>max</sub> by 20% and AUC by 27%. EGT710 700 mg once daily for 7 days modestly induced CYP3A4 activity but had no effect on organic anion transporting polypeptide (OAT1/3) activity. Oral EGT710 (capsule and suspension) was safe and well tolerated, with pharmacokinetics that support further development as a treatment for coronavirus disease.</p>","PeriodicalId":10495,"journal":{"name":"Clinical Pharmacology in Drug Development","volume":"15 10","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cpdd.70115","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149259241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jianxin Wang, Kai Gu, Mingxuan Zhang, Miao Yu, Pei Zhao, Jing Yu, Xiaohong Guo, Yating Bai, Jie Liu, Xiaoli Wang, Xiaolai Yang
{"title":"A Bioequivalence Study of Two Formulations of Enzalutamide Soft Capsules in Healthy Chinese Male Subjects","authors":"Jianxin Wang, Kai Gu, Mingxuan Zhang, Miao Yu, Pei Zhao, Jing Yu, Xiaohong Guo, Yating Bai, Jie Liu, Xiaoli Wang, Xiaolai Yang","doi":"10.1002/cpdd.70121","DOIUrl":"10.1002/cpdd.70121","url":null,"abstract":"<p>Enzalutamide is an oral second-generation androgen receptor inhibitor used for advanced prostate cancer. This study evaluated the pharmacokinetics (PK), bioequivalence (BE), and safety of a newly developed generic enzalutamide soft capsule (test) compared with the reference product (XTANDI) in healthy Chinese adults under fasting and fed conditions. A single-center, randomized, open-label, two-period, two-sequence, crossover study was conducted in 72 male participants (36 fasting and 36 fed). Each participant received a single 40-mg dose of test or reference formulation, separated by a 34-day washout. Blood samples were collected up to 72 h post-dose. PK parameters (C<sub>max</sub> and AUC<sub>0-72 h</sub>) were calculated using non-compartmental analysis. BE was assessed by 90% confidence intervals (CIs) of geometric mean ratios (GMRs). Safety was monitored throughout the study. In both fasting and fed conditions, the 90% CIs of GMRs for C<sub>max</sub> and AUC<sub>0-72 h</sub> were within the predefined 80%–125% BE range. Both formulations exhibited a favorable single-dose safety profile, with no serious adverse events reported. The test enzalutamide soft capsule is bioequivalent to the reference product in healthy Chinese volunteers, demonstrating similar PK profiles and safety. This study provides population-specific PK evidence supporting the clinical use of the generic formulation in China.</p>","PeriodicalId":10495,"journal":{"name":"Clinical Pharmacology in Drug Development","volume":"15 10","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13689526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149243534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Romina A. Nand, Hannah Woodcock, Kasia A. Okrojek-Swiderek, Yolanda Alvarez, Mohak Sharda, Anubha Gupta
{"title":"Pharmacokinetics and Safety Evaluation of the Transglutaminase 2 Inhibitor Suvigletistat in Healthy Chinese, Japanese, and White/European Participants","authors":"Romina A. Nand, Hannah Woodcock, Kasia A. Okrojek-Swiderek, Yolanda Alvarez, Mohak Sharda, Anubha Gupta","doi":"10.1002/cpdd.70113","DOIUrl":"10.1002/cpdd.70113","url":null,"abstract":"<p>This Phase I, randomized, placebo-controlled, double-blind study (NCT06625489) evaluated pharmacokinetics (PK), safety, and tolerability of the transglutaminase 2 inhibitor suvigletistat in Chinese, Japanese, and White/European participants. Eligible participants: aged 18–50 years, healthy, and of Chinese, Japanese, or White/European ancestry. Thirty-six participants (12 per ancestry group) were randomized 3:1 to receive suvigletistat (160 mg single oral dose) or placebo. Suvigletistat was rapidly absorbed (median time to maximum observed drug concentration [C<sub>max</sub>]: 0.67–0.75 h), and geometric mean half-life ranged from 1.93 to 2.58 h across ancestry groups. Suvigletistat systemic exposure was similar across all ancestries; geometric least squares mean ratios versus White/European participants for C<sub>max</sub> were 0.99 and 1.06 in participants of Chinese and Japanese ancestry, respectively. Similarly, area under the concentration–time curve from time zero to infinity ratios were 0.94 and 1.06. Suvigletistat geometric mean elimination half-life was comparable in Chinese (1.93 h), Japanese (2.23 h), and White/European participants (2.58 h). There were no serious adverse events or deaths. There were no clinically meaningful findings in laboratory values, vital signs, or electrocardiograms. No clinically meaningful differences in suvigletistat PK were observed between ancestry groups, providing evidence of low ethnic sensitivity for a drug with cytochrome P450 3A4-dependent metabolism.</p>","PeriodicalId":10495,"journal":{"name":"Clinical Pharmacology in Drug Development","volume":"15 10","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149237182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Formulation-Dependent Modulation of Ibuprofen Absorption Kinetics in Fixed-Dose Combinations: An Exploratory Analysis of the Dissolution–Absorption Relationship","authors":"Satoko Ueda, Mitsuaki Chujo, Nobuo Miyadai, Clemence Rauch, Valentine Polivka, Yujin Saito, Ichiro Kawase, Naoki Uchida, Shunji Matsuki","doi":"10.1002/cpdd.70112","DOIUrl":"10.1002/cpdd.70112","url":null,"abstract":"<p>We conducted a pharmacokinetic study to compare two fixed-dose combinations of ibuprofen/acetaminophen (IP-TA and IP-TB) with different formulation designs and excipient compositions, and explored how formulation differences influence ibuprofen pharmacokinetics by comparing in vitro dissolution and in vivo absorption profiles. In an open-label, randomized, 2-treatment, 2-period, 2-sequence crossover study, 24 healthy Japanese participants received a single oral dose of IP-TA (ibuprofen 195 mg and acetaminophen 195 mg) or IP-TB (ibuprofen 160 mg and acetaminophen 160 mg) under fasting conditions. Pharmacokinetic data were analyzed using a linear mixed-effects model. Fraction absorbed (F<sub>a</sub>) was estimated using the Loo–Riegelman method, and ibuprofen dissolution was evaluated at pH 1.2, 4.0, and 6.8. The relationship between weighted mean dissolution rates (D) and F<sub>a</sub> was examined. Ibuprofen absorption from IP-TA was faster than from IP-TB, as reflected by higher C<sub>max</sub> and greater early exposure, and these differences remained after dose normalization. Dissolution profiles showed temporal similarity with absorption profiles, particularly for IP-TA. Analysis of F<sub>a</sub> also suggested a relatively high degree of synchronization between ibuprofen and acetaminophen absorption in IP-TA. These findings indicate that formulation-dependent differences in dissolution behavior may influence early ibuprofen absorption, although further studies are needed to clarify the underlying mechanisms.</p>","PeriodicalId":10495,"journal":{"name":"Clinical Pharmacology in Drug Development","volume":"15 10","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"When Clinical Pharmacology Cannot Wait for Complete Data: Reflections Following the 2026 ACCP Annual Meeting","authors":"Amalia M. Issa","doi":"10.1002/cpdd.70117","DOIUrl":"10.1002/cpdd.70117","url":null,"abstract":"<p>Another American College of Clinical Pharmacology (ACCP) Annual Meeting is successfully in the books. As always, the meeting offered a wide range of stimulating symposia and sessions as well as many thoughtful conversations that stayed with many of us well after the rooms emptied. Among them, Symposium 1, “Where Are We Now in Pediatric Cancer Drug Development: 5 Years of the RACE for Children Act,” brought together perspectives from FDA, industry, and pediatric oncology on a question that is both technically demanding and deeply human: how do we move promising therapies toward children with cancer when the evidence can never be as abundant as we would like?</p><p>That question becomes real when we picture the child in front of us: a child with a serious, life-threatening rare disease and no approved treatment. A therapy may have compelling biology and encouraging adult data, yet the appropriate pediatric dose, exposure target, benefit–risk profile, and durability of response remain incompletely characterized. In that moment, clinical pharmacologists are asked to confront a difficult but increasingly common question: should development wait for conventional evidentiary completeness, or should the available evidence be integrated quantitatively to support a timely, proportionate, and ethically defensible decision?</p><p>This question should not be construed as an invitation to lower evidentiary standards. Rather, it requires standards that are fit for purpose when large dose-ranging studies, conventional randomized trials, or extensive pediatric efficacy programs are infeasible, unacceptably slow, or ethically difficult to conduct. In pediatric rare diseases, the relevant goal is not “perfect” evidence. It is an evidence package that is mechanistically coherent, quantitatively rigorous, transparent about uncertainty, and appropriate to the severity of the condition, the unmet need, and the feasibility of obtaining additional data.</p><p>The ACCP Annual Meeting brought renewed focus to this central challenge in drug development. Discussions spanning pediatric oncology, pediatric extrapolation, model-informed dose selection, and rare-disease development underscored an expanding responsibility for clinical pharmacology: to transform sparse, fragmented, and heterogeneous evidence into decisions that are scientifically credible and clinically useful.</p><p>For readers of CPDD, this is not a peripheral issue. It lies at the intersection of pharmacokinetics, pharmacodynamics, translational science, quantitative systems pharmacology, regulatory science, and therapeutic decision-making. Clinical pharmacology is increasingly expected not merely to describe variability, but to explain it, predict its consequences, and guide action despite residual uncertainty.</p><p>Pediatric drug development has long been constrained by small populations, developmental heterogeneity, ethical limits on research participation, and delayed integration of pediatric plans into","PeriodicalId":10495,"journal":{"name":"Clinical Pharmacology in Drug Development","volume":"15 10","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cpdd.70117","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kai Bin Liew, Kar Ming Yee, Jeyashanthini Nalaiya, Atiqah Amran, Khairil Aswad Othman
{"title":"Pharmacokinetic and Bioequivalence of Mirtazapine Orally Disintegrating Tablets: A Randomized, Crossover Study","authors":"Kai Bin Liew, Kar Ming Yee, Jeyashanthini Nalaiya, Atiqah Amran, Khairil Aswad Othman","doi":"10.1002/cpdd.70110","DOIUrl":"10.1002/cpdd.70110","url":null,"abstract":"<p>The study aimed to assess the bioequivalence of a new generic orally disintegrating tablet (ODT) formulation containing mirtazapine 30 mg with the reference formulation, and to support biowaiver for an additional 15 mg strength. Fifty-five healthy Malaysian males completed an open-label, balanced, randomized, 2-treatment, 2-period, single oral dose study with a 14-day washout period under fasting conditions. Each participant received a single 30 mg dose of mirtazapine test or reference ODT. Plasma concentrations of mirtazapine up to 72 h post-dose were quantified using a validated high-performance liquid chromatography-tandem mass spectrometry detection method following a liquid-liquid extraction. Non-compartmental analysis was used to derive the pharmacokinetic parameters, which were then compared between the test and reference formulations using a multivariate analysis of variance. The pharmacokinetic parameters of the test formulation were not statistically different from the reference formulation. The 90% confidence intervals of mirtazapine for AUC<sub>0–72</sub> and <i>C</i><sub>max</sub> concentration were within 80%-125% based on the bioequivalence acceptance range criteria. The test and reference formulations of mirtazapine 30 mg ODT are bioequivalent and well tolerated under fasting conditions. These findings support the extrapolation of bioequivalence and the justification of a biowaiver for the additional mirtazapine ODT 15 mg strength.</p>","PeriodicalId":10495,"journal":{"name":"Clinical Pharmacology in Drug Development","volume":"15 10","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}